How did AYTU's Q3 2025 EPS forecast compare to past trends?

Aytu BioPharma's Q3 2025 EPS forecast is not currently available. However, by analyzing the company's past performance, we can make informed predictions about its future trends.

1. **Consistent Improvement in Financial Performance**: Aytu BioPharma has shown a consistent improvement in its financial performance over the past years. In Q3 2024, the company reported a GAAP EPS of -$0.52, which beat the analyst estimate by $0.12. This indicates a positive trend in the company's earnings.

2. **Strategic Focus on Rx Segment**: The company's strategic focus on its Rx Segment has led to a significant increase in net revenue. The ADHD Portfolio net revenue increased by 23% compared to fiscal 2023. This suggests that the company's focus on its core business is paying off and could lead to further improvements in financial performance.
3. **Positive Outlook for Fiscal 2025**: The company expects net revenue growth across the Rx Segment in fiscal 2025. This positive outlook, combined with the recent improvements in financial performance, suggests that Aytu BioPharma is on a path to recovery and growth.

In conclusion, Aytu BioPharma's Q3 2025 EPS forecast is likely to be positive, considering the company's consistent improvement in financial performance, strategic focus on the Rx Segment, and positive outlook for the future.